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Objective: To evaluate the efficacy of a combination of bioidentical combined 17β-estradiol and 
progesterone transdermal delivery system (lipophilic emulsion-type base) to relieve climacteric 
symptoms. The hormonal replacement was given during a period of 6 months at four different 
cyclic doses to mimic the normal ovary secretory pattern.
Design: An open, randomized, comparative, between-patient trial conducted over 6 months 
in 29 menopausal women with climacteric symptoms assessed with the Kupperman index at 
baseline and during treatments. Saliva and serum values of 17β-estradiol and progesterone 
were quantitated before treatment and after 3 and 6 months. Pharmacokinetic data following 
transdermal administration of 17β-estradiol (0.3 mg, daily) and progesterone (100 mg, daily) 
were calculated from saliva levels using high-performance liquid chromatography analysis.
Results: Improvement in climacteric symptoms was reported in 93% of women evaluated 
before and after 3 and 6 months of treatment. Values of saliva 17β-estradiol increased after 
6 months from 0.6 ± 0.3 pg/mL to 14.1 ± 3.3 pg/mL, and the values of serum 17β-estradiol 
increased from 3.3 ± 2.8 pg/mL to 80.6 ± 21.9 pg/mL. Of responders, 88% characterized 
symptom relief as complete. No adverse health-related events were attributed to the bioidentical 
hormone therapy. Time to maximum saliva concentrations (Tmax), in all experimental cases, 
was observed after 6 hours. Baseline values were reached within 24 hours, indicating a diurnal 
rhythm of 17β-estradiol seen in normally cyclic women over the 24-hour period, ie, its daily 
biological rhythm.
Conclusion: Percutaneous absorption of 17β-estradiol, as well as the absorption of progester-
one, was associated with relief of climacteric symptoms. The cyclical transdermal delivery of 
combined bioidentical hormones may be advantageous because it mimics the secretory profiles 
of 17β-estradiol and progesterone in normally cyclic women over a 28-day period. Larger   studies 
are needed to determine the long-term effects of our therapy.
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Introduction
Ovarian hormone production in women peaks at the age of 25 years. After that, the 
decline is about 1%–3% annually. By the time a woman reaches 40 years, hormone 
production has fallen off 15%–45%. Although the average age of menopause (the 
final monthly cycle) is 51 years, it takes decades of declining hormone production to 
get there. Only a very small amount of 17β-estradiol is still produced from adrenal 
  precursors. More than 70% of all postmenopausal women suffer at various periods 
of time from the symptoms of this estrogen deficiency, most notably vasomotor 
  instability (hot flashes) and sleep disturbances. The tropic symptoms of estrogen 





bone density that eventually increases the risk of fractures; 
genitourinary atrophy resulting in dyspareunia and urinary 
atrophy; and lipoprotein changes with increased risk of 
coronary heart morbidity and mortality.1
Today, estrogen deficiency is mainly treated by oral 
estrogens (either conjugated equine urine-derived estrogens 
containing ,0.2% 17β-estradiol) in doses far in excess 
of what would be required by the parenteral route. Taken 
orally, estradiol is largely transformed to estrone through 
metabolism in the liver. Dosage for parenteral estrogen 
administration has been widely studied, including the dif-
ferent forms, eg, percutaneous creams, intranasal solutions, 
and vaginal gel. All of these administration forms result 
in a pronounced, transient elevation of plasma and saliva 
concentrations of 17β-estradiol, with little conversion to 
estrone and no first-pass hepatic effect, thus avoiding an 
increase in hepatic protein synthesis. Daily doses of 0.5 mg 
or less achieving estradiol plasma levels between 65 pg/mL 
and 90 pg/mL are threshold values effective in reducing hot 
flashes.2   Endocrinological changes and dynamics   during 
the menstrual cycle are described in detail elsewhere.2 
This article refers to plasma concentrations.
Detailed analyses of the rhythms are difficult due to 
problems with sampling. The most convenient solution to 
this problem is the measurement of sex steroid concentrations 
in other biological fluids that are more easily available, such 
as urine or saliva. However, urinary values give only partial 
information of sex steroid metabolites. Sex steroids leak into 
saliva from plasma. However, only the free unbound fraction 
is involved. Albumin and sex hormone-binding globulin do 
not allow the bound fraction of the hormones to get into 
saliva, due to their molecular weights. Thus, salivary con-
centrations represent a valuable marker for the free, unbound, 
and biologically active fraction of the particular steroid.2
The dynamics of salivary steroids resemble the known 
dynamics in plasma.3 Saliva estradiol reaches the lowest 
levels during the early menstrual phase and the highest just 
around ovulation and at a secondary peak in the late luteal 
phase.3 Progesterone produced mainly by corpus luteum is 
found in the highest saliva concentrations during the luteal 
phase.2 Salivary hormone levels and their pattern during 
cyclic 17β-estradiol and progesterone percutaneous sex 
hormone replacement therapy have not been studied in such 
a manner yet.
The aim of our study was to use a combined estradiol 
and progesterone transdermal cream to i) estimate the 
saliva and serum levels of hormones after 3 and 6 months 
of administration of four various low doses of transdermal 
17β-estradiol and progesterone designed to mimic the 
secretory 28-day   pattern seen in a normal, healthy cycling 
women; ii) determine whether such a protocol ameliorates 
climacteric symptoms; and iii) investigate the diurnal rhythm 
of 17β-estradiol by pharmacokinetic assessment of hormone 
uptake at various time points during a period of 24 hours after 
application of the cream.
Methods
The study in postmenopausal women was performed in 
Santa Barbara, California, USA, according to an open, 
  nonrandomized, between-patient trial. The study proto-
col were reviewed and approved by the Internal Ethics 
  Committee, Cottage Hospital, Santa Barbara. Each subject 
received oral and written information on the study and all 
signed a formal consent.
Twenty-nine healthy, nonhysterectomized women 
(age 44–56 years, mean 51 years) undergoing the physiologi-
cal menopause (.1year of amenorrhea) were enrolled in the 
trial and all completed the study. Ovariprival status was con-
firmed by plasma follicle-stimulating hormone (FSH) levels 
above 60 U/L, saliva 17β-estradiol levels below 1.0 pg/mL, 
and serum 17β-estradiol levels below 4 pg/mL. None of the 
subjects had received sex steroids or other specific drugs for 
at least 8 weeks before evaluation.
All patients had typical symptoms of the climacteric 
syndrome and a Kupperman index (which takes into account 
the 11 most common symptoms corrected both by a weight 
factor and by a severity coefficient) of over 25.4 Patients were 
excluded if they had undiagnosed vaginal bleeding; severe 
metabolic, endocrine, or gastrointestinal disease; neoplasms; 
uncontrolled hypertension; or endometriosis or if they were 
smokers or were known to be alcohol or drug abusers.
The hormones under investigation were micronized 
17β-estradiol combined with micronized progesterone 
in a lipophilic base cream developed for transdermal 
  administration. The cream was packed in units of seven 
wells, each containing 1 mL of cream. Hormones from a 
total of four units containing four different doses of com-
bined 17β-estradiol plus progesterone were administered 
during a period of 4 weeks. A new 4-week cycle was then 
started. Hormone doses applied were as follows: 0.05 mg/mL 
17β-estradiol plus 25 mg/mL progesterone administered daily 
during week 1, 0.30 mg/mL 17β-estradiol plus 50 mg/mL 
  progesterone administered daily during week 2, 0.20 mg/mL 
17β-estradiol plus 100 mg/mL progesterone administered 
daily during week 3, and 0.10 mg/mL 17β-estradiol plus 
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The   subjects applied 1 mL of the cream on a specific small 
area of ∼200 cm² of the anterior thigh. On study days, as well as 
days with saliva sampling, the cream was applied at 08.00.
For determination of 17β-estradiol and progesterone at 
baseline, saliva and blood samples were taken on day 1 before 
the first application of the cream. Samples were taken on day 
6 of week 2 at T = 6 hours after 3 and 6 months of treatment. 
Serum FSH and 17β-estradiol were assayed by extraction 
chromatography and radioimmunoassay. For pharmacoki-
netic data, saliva samples were taken on day 6 of week 2 
immediately before application and then subsequently after 
6, 12, and 24 hours. Saliva 17β-estradiol and progesterone 
concentrations were analyzed using high-performance liquid 
chromatography (HPLC) analysis (PerkinElmer® Series 200 
HPLC system; PerkinElmer Life and Analytical Sciences, 
Shelton, CT, USA).
For statistics, all data were analyzed by a means model 
repeated-measures analysis of absolute changes from base-
line with SAS Proc Mixed® (Version 8.02, SAS Institute 
Inc., Cary, NC, USA) and shown as the arithmetic mean ± 
standard deviation.
Results
As shown in Table 1, plasma levels of FSH presented a sig-
nificant fall at each time point versus baseline. There was a 
similar significant fall in the Kupperman index after 3 and 
6 months of treatment versus baseline.
 After 3 and 6 months of treatment, saliva 17β-estradiol 
and progesterone levels significantly increased, as shown 
in Table 2. Mean observed 17β-estradiol saliva concentra-
tions obtained with week 2 protocol designed to mimic 
week 2 of the menstrual cycle (0.30 mg/mL 17β-estradiol 
plus 50 mg/mL progesterone) on day 6, 6 hours after 
morning application, significantly increased after 3 and 
6 months of treatment. Each time point versus baseline 
was significantly increased to saliva values close to those 
of the early follicular phase3 (0.6 ± 0.3 vs 10.4 ± 2.6 vs 
14.1 ± 3.3 pg/mL; P , 0.01). The ratio between baseline 
value and 6-month treatment value was 23.5. Mean observed 
saliva   progesterone levels were significantly increased. Also, 
serum 17β-estradiol   concentrations increased significantly 
(3.3 ± 2.8 vs 47.9 ± 14.7 vs 80.6 ± 19.9 pg/mL; P , 0.01). 
The ratio of baseline value and 6-month treatment value 
was 24.2, which is of same magnitude as the saliva data 
(23.5), indicating a correlation between saliva and serum 
17β-estradiol levels.
 Saliva samples for pharmacokinetic assessment were 
  collected at various time points on day 6 of week 2: T = 0 
(just before morning application ), T = 6, T = 12, and 
T = 24 hours after application of the cream. Mean saliva 
concentration–time profiles of 17β-estradiol and proges-
terone are shown in Table 3. Highest saliva levels of both 
hormones were observed 6 hours after application. Saliva 
levels decreased to levels close to baseline values 24 hours 
after application. A similar diurnal rhythm is observed in 
normally cyclic women during reproductive life.
Discussion
This open, between-patient study validated a novel concept 
of biorhythmic estrogen therapy achieved by transdermal 
administration of 17β-estradiol during periods of 4 weeks, 
where four different doses of 0.05 mg, 0.30 mg, 0.20 mg, or 
0.10 mg, respectively, were applied daily during 4 consecu-
tive weeks to highly symptomatic women. Also,   biorhythmic 
doses of progesterone were administrated daily in doses of 
25 mg, 50 mg, 100 mg, or 100 mg progesterone, respec-
tively, each of the consecutive weeks. The study ended after 
6 months of treatment without adverse effects. The study 
demonstrated that transdermal 17β-estradiol plus progester-
one significantly reduced the number of objectively measured 
hot flashes and relieved typical climacteric   symptoms, as 
evaluated by   multiple clinical criteria (Kupperman index). 
The positive effect was present after 3 months, and subse-
quently was enhanced after 6 months. The physiological 
importance of our study is highlighted by saliva concentra-
tions obtained by week 2 that closely mimic the estradiol 
maximal level typifying the early follicular phase of the 
normal menstrual cycle.3 Simultaneously, serum levels of 
17β-estradiol were estimated before and after 3 and 6 months 
of treatment. The concentration increased from 3.3 pg/mL to 
80.6 pg/mL, which is a value sufficient to relieve climacteric 
symptoms.1,2
The pharmacokinetic experiments showed that highest 
saliva concentrations of 17β-estradiol and progesterone were 
obtained 6 hours after morning application of the cream. 
Twenty-four hours after application, saliva concentrations 
of both steroids reached baseline values. This is the first 
Table 1 Serum follicle-stimulating hormone (FSh) in mIU/mL and 
Kupperman index before and during transdermal 17β-estradiol 





Basal 128 ± 28.2 30.3 ± 5.4
3 months 90.8 ± 11.9* 11.1 ± 3.2**
6 months 44.4 ± 13.0** 5.2 ± 2.2**





time a biorhythmic protocol has been applied for treatment 
of climacteric symptoms, which prompts the question of 
whether 17β-estradiol in biorhythmic cyclic doses adminis-
tered to postmenopausal women contributes to realignment 
of biological time linked to reproductive cycles. In mammals, 
most body functions follow a rhythmic pattern adjusted to a 
24-hour period. Circadian rhythmicity is an evolutionarily 
conserved property that regulates numerous functions in 
the human body, including sleep and   wakefulness, body 
temperature, blood pressure, hormone production,   digestive 
secretion, and immune activity.5 A central rhythm genera-
tor is located in the suprachiasmatic nucleus (SCN) of the 
hypothalamus and consists of multiple, autonomous single-
cell circadian oscillators, which are synchronized to fire 
rhythmically, generating a coordinated, rhythmic output in 
intact animals.6
Interestingly, it has been demonstrated that as many 
as one-third of the neurons afferent to the SCN are estro-
gen receptor α-immunoreactive.7 The cellular mechanism 
of circadian rhythmicity involves the regulation of three 
Period genes (Per 1–3) and two cytochrome genes (Cry 1 
and Cry).6 Per-2 has been reported to function as a tumor 
suppressor gene.8 Per-2 is expressed in normal mammary 
epithelium and at a reduced level in breast cancer cells, 
leading to an   alteration in the cell cycle, cell growth, and cell 
survival. The biological clocks are synchronized by central 
  pacemaker through complex interaction of neural, humoral, 
and   behavioral cues.9 A variety of factors have been unrav-
eled with the potential to reset circadian rhythms in SCN and 
peripheral cells, such as estradiol and progesterone,10,11 by 
inducing an acute   activation of Per-1 and Per-2 expression.
It is therefore of considerable interest to consider the pos-
sibility that endogenous fluctuations in estradiol and proges-
terone levels may modulate clock gene expression in SCN, 
as well as in a number of peripheral tissues. Moreover, given 
the proposed association between clock gene expression, the 
cell cycle, and tumor growth, this is one route through which 
estradiol and progesterone in cycling low doses that mimic 
a normal menstrual cycle might downregulate susceptibility 
to cancer development.12–14
The menstrual cycle is an endocrine clock orchestrated 
by circulating levels of ovarian steroids, ie, estrogen and 
progesterone. The biological actions of estrogens are medi-
ated mainly by estrogen receptors (ERα and ERβ), which 
bind to estrogen response elements in the regulatory regions 
of target genes and associate with basal transcription fac-
tors and tissue-specific cofactors to alter gene expression.15 
Because the transcriptional regulation is a key feature of 
both the circadian machinery and the ER pathway and the 
proposed connection between the clock genes and breast 
cancer, Gery and Koeffler13 suggested that the ER signaling 
is yet another front on which core clock factors may exert 
their effects. It was found13 that Per2 is a novel estrogen-
inducible ER cofactor. Per2 binds to ERα, enhances 
receptor degradation, and suppresses estrogen-mediated 
transcription of ER target genes in breast cancer cells. 
In turn, Per2 itself is estrogen inducible in these cells, hence 
suggesting a feedback mechanism to attenuate estrogen 
response that couples the circadian clock to the estrogen 
pathway. Linking Per2 to the estrogen pathway indicates a 
strong tumor suppressor function in breast tissue that leads 
to proliferation arrest, growth inhibition, and apoptosis 
associated with downregulated expression of Cyclin D1, 
c-Myc, and p21.13
Table 2 Saliva 17β-estradiol and progesterone and serum 17β-estradiol. Samples were collected 6 hours after morning application on 
day 6 of the week 2 protocol (0.3 mg estradiol plus 100 mg progesterone). Basal values represent concentrations before treatments 
(mean ± standard deviation)
Saliva 17β-estradiol pg/mL 
(n = 16)




Basal 0.6 ± 0.3 3.3 ± 2.8 135 ± 51
3 months 10.4 ± 2.6* 47.9 ± 16.7* 2414 ± 144*
6 months 14.1 ± 3.3* 80.6 ± 21.9* 2840 ± 276*
Note: *P , 0.01 vs baseline.
Table 3 Dynamic changes of saliva 17β-estradiol and progesterone 
after  6  months  of  treatment.  Saliva  samples  were  collected 
during day 6 after application of week 2 protocol (0.3 mg 17β-
estradiol plus 100 mg progesterone) at various time points (h) 





T = 0   4.1 ± 2.0   682 ± 119
T = 6 18.8 ± 4.0* 1812 ± 211*
T = 12 12.2 ± 4.2* 1613 ± 445*
T = 24   5.3 ± 2.4   856 ± 114
Note: *P , 0.01 vs baseline.International Journal of General Medicine
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The finding that circadian oscillators in select regions of 
the limbic forebrain are modulated by endogenous changes in 
estrogen adds a previously unrecognized level of complexity 
to the organization of the circadian system.16 Hence, consid-
ering the strong relationships between sleep difficulties and 
depressive symptoms, the control of circadian rhythms by 
estrogen-regulated molecular mechanisms described previ-
ously may represent a novel biomedical area that indirectly 
affects the mood and wellbeing of menopausal women. The 
significance of these findings is also in favor of an implication 
of estrogen in the modulation of neuronal activity in SCN 
and thus possibly its ability to re-establish circadian rhythms 
in menopausal women.
All the women before the study had severe climacteric 
symptoms, as indicated by a Kupperman index of 30. After 
6 months of hormone treatment, these symptoms were sig-
nificantly attenuated and the Kupperman index decreased 
to a value of 7. In particular, the ability to fall asleep, 
decreased restlessness, and reduced depressive symptoms 
were observed, which suggests that a synchronization 
  (Zeitgeber mechanism) between circadian clock rhythms and 
the rhythms of estradiol rise and fall during treatment might 
have taken place in the control center for the menopausal 
women’s sleep cycles.
Based on these results, we propose that investigators 
must translate both basic science and clinical outcomes to 
decide the safest, most efficacious treatment for patients with 
climacteric symptoms. Evidence-based medicine involves the 
synthesis of all available data when comparing therapeutic 
options for patients. But evidence-based medicine does not 
mean that data from pilot studies should be ignored until a 
randomized controlled trial of particular size and duration is 
completed. Rather, it demands an assessment of the current 
available data to decide which therapies are likely to carry 
the greatest benefits and lowest risk for patients. Based on 
both physiological results and clinical outcome, our study 
demonstrates that bioidentical hormones are associated with 
better clinical results than their nonbiological counterparts. 
Until there is evidence to the contrary, bioidentical hormones 
transdermally17,18 administered in biorhythmic cyclic doses 
are the preferred modality of HRT. But larger studies are 
needed to determine the long-term (5–10 years) effects of 
the therapy.
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